Debt-to-equity of SAB Biotherapeutics, Inc. from 30 Sep 2021 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: SAB Biotherapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 31 Dec 2025.
SAB Biotherapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 21%, a 50% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

SAB Biotherapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	21%	-22%	-50%	31 Dec 2025
Q3 2025	32%	-8.5%	-21%	30 Sep 2025
Q2 2025	73%	+29%	+68%	30 Jun 2025
Q1 2025	52%	+0.84%	+1.7%	31 Mar 2025
Q4 2024	43%	-20%	-32%	31 Dec 2024
Q3 2024	40%	-34%	-46%	30 Sep 2024
Q2 2024	43%	-28%	-40%	30 Jun 2024
Q1 2024	51%	-16%	-24%	31 Mar 2024
Q4 2023	63%	-2%	-3%	31 Dec 2023
Q3 2023	74%	-3.2%	-4.2%	30 Sep 2023
Q2 2023	72%	+4.4%	+6.5%	30 Jun 2023
Q1 2023	67%	+8.2%	+14%	31 Mar 2023
Q4 2022	65%	+19%	+41%	31 Dec 2022
Q3 2022	77%	+48%	+161%	30 Sep 2022
Q2 2022	67%			30 Jun 2022
Q1 2022	59%			31 Mar 2022
Q4 2021	46%			31 Dec 2021
Q3 2021	30%			30 Sep 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.